Primo Biotechnology wins 2026 Taiwan BIO Award

Primo Biotechnology was named the 2026 Taiwan BIO Award Startup of the Year in Taipei, Taiwan, as the radiopharmaceutical startup pushes its Primo-X theranostics platform toward commercialization. The company is building a prostate cancer-focused pipeline and plans local manufacturing, Taiwan expansion and broader Asia-Pacific licensing.

Why it matters: - Primo Biotechnology is trying to build one of Taiwan’s first end-to-end radiopharmaceutical platforms, from diagnosis to therapy. - The award spotlights the company’s push into radiotheranostics, a cancer care market that depends on precision imaging and targeted treatment. - Primo’s plan could reduce Taiwan’s reliance on imported therapeutic nuclear medicine and strengthen local drug supply resilience.

What happened: - Primo Biotechnology Co., Ltd. won the "2026 Taiwan BIO Award – Startup of the Year" in Taipei. - The company is a Taiwanese startup focused on radiopharmaceuticals and cancer precision medicine. - Primo framed the award as recognition of its platform model and growth potential.

The details: - Primo started in 2021 and built its strategy around the Primo-X Theranostics Platform. - The platform follows a theranostics model that starts with precision diagnosis and ends with precision therapy. - Primo is combining drug discovery, GMP manufacturing, clinical translation, hospital integration and international expansion. - Primo says it is one of the few advanced nuclear medicine companies in Taiwan with capabilities across radiopharmaceutical production, clinical research, GMP manufacturing, clinical translation and commercialization. - The company is active in global nuclear medicine circles, including the Society of Nuclear Medicine and Molecular Imaging. - Primo has pursued partnerships with global and industry peers in medical imaging, radionuclide supply, drug licensing, clinical translation and market expansion. - The company has also received the National Innovation Award, the TAIPEI Prominent Enterprise Award and the Ministry of Economic Affairs' Potential Startup Award. - Primo has also received research and development grant support from the Department of Economic Development. - Primo says it has moved from R&D toward productization and commercialization, with foundations in nuclear medicine supply, product revenue, hospital channels, contract manufacturing, clinical translation and international collaborations. - Chairman and CEO Dr. Ya-Yao Huang said the company’s core belief is: "See what you treat. Treat what you see." - Primo’s first therapeutic focus is prostate cancer. - PB01 is the company’s PSMA-targeted precision imaging diagnostic drug. - PB01 is currently in the TFDA regulatory approval phase and is expected to launch in Taiwan. - PBT01 is the therapeutic radiopharmaceutical paired with PB01. - PBT01 has completed preclinical safety and efficacy evaluations and three batches of process validation. - Primo plans to begin Phase I/II clinical trials for PBT01 in Taiwan. - Primo is also expanding PB01 into new indications and advancing PB012 for precision cancer diagnostics. - Primo said all product development, clinical trials and market launches will follow regulatory review and approval processes. - Dr. Huang said radiopharmaceuticals are time-sensitive strategic medical assets because of their short half-lives and cannot be stockpiled. - Primo is pursuing local manufacturing to reduce Taiwan’s dependence on imported therapeutic nuclear medicine.

Between the lines: - Primo is pitching itself as more than a drug developer; the company is selling a platform story that ties together manufacturing, clinical evidence and cross-border commercialization. - The company’s three-tier plan points to a staged strategy: near-term product sales, mid-term clinical expansion and long-term Asia-Pacific licensing and co-development. - The Taiwan BIO honor may help validate Primo’s bid to become a regional radiotheranostics supplier rather than a single-product startup.

What's next: - Primo expects TFDA approval and a Taiwan launch for PB01. - The company plans to start Phase I/II trials for PBT01 in Taiwan. - Primo will keep expanding therapeutic radiopharmaceutical pipelines and indications. - The company aims to grow cross-border licensing, co-development and market expansion across the Asia-Pacific region. - Primo wants Taiwan to become an innovation and supply hub for radiopharmaceuticals.

The bottom line: - Primo Biotechnology is turning an award win into momentum for a broader push in radiotheranostics, with prostate cancer products, local manufacturing and regional expansion at the center of its plan.